Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2016

01.03.2016 | Gynecologic Oncology

Predictive Modeling: A New Paradigm for Managing Endometrial Cancer

verfasst von: Sofiane Bendifallah, MD, Emile Daraï, MD, PhD, Marcos Ballester, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

With the abundance of new options in diagnostic and treatment modalities, a shift in the medical decision process for endometrial cancer (EC) has been observed. The emergence of individualized medicine and the increasing complexity of available medical data has lead to the development of several prediction models. In EC, those clinical models (algorithms, nomograms, and risk scoring systems) have been reported, especially for stratifying and subgrouping patients, with various unanswered questions regarding such things as the optimal surgical staging for lymph node metastasis as well as the assessment of recurrence and survival outcomes. In this review, we highlight existing prognostic and predictive models in EC, with a specific focus on their clinical applicability. We also discuss the methodologic aspects of the development of such predictive models and the steps that are required to integrate these tools into clinical decision making. In the future, the emerging field of molecular or biochemical markers research may substantially improve predictive and treatment approaches.
Literatur
1.
2.
Zurück zum Zitat Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105;103–4.CrossRefPubMed Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105;103–4.CrossRefPubMed
3.
Zurück zum Zitat Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63: 11–30.CrossRefPubMed Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63: 11–30.CrossRefPubMed
4.
Zurück zum Zitat Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S105–43.CrossRefPubMed Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S105–43.CrossRefPubMed
5.
Zurück zum Zitat Kinkel K, Forstner R, Danza FM, et al. Staging of endometrial cancer with MRI: guidelines of the European Society of Urogenital Imaging. Eur Radiol. 2009;19:1565–74.CrossRefPubMed Kinkel K, Forstner R, Danza FM, et al. Staging of endometrial cancer with MRI: guidelines of the European Society of Urogenital Imaging. Eur Radiol. 2009;19:1565–74.CrossRefPubMed
6.
Zurück zum Zitat Haldorsen IS, Salvesen HB. Staging of endometrial carcinomas with MRI using traditional and novel MRI techniques. Clin Radiol. 2012;67:2–12.CrossRefPubMed Haldorsen IS, Salvesen HB. Staging of endometrial carcinomas with MRI using traditional and novel MRI techniques. Clin Radiol. 2012;67:2–12.CrossRefPubMed
7.
Zurück zum Zitat Ballester M, Dubernard G, Lécuru F, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol. 2011;12:469–76.CrossRefPubMed Ballester M, Dubernard G, Lécuru F, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol. 2011;12:469–76.CrossRefPubMed
8.
Zurück zum Zitat Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol. 2012;13:e353–61.CrossRefPubMed Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol. 2012;13:e353–61.CrossRefPubMed
9.
Zurück zum Zitat Morneau M, Foster W, Lalancette M, et al. Adjuvant treatment for endometrial cancer: literature review and recommendations by the Comité de l’évolution des pratiques en oncologie (CEPO). Gynecol Oncol. 2013;131:231–40.CrossRefPubMed Morneau M, Foster W, Lalancette M, et al. Adjuvant treatment for endometrial cancer: literature review and recommendations by the Comité de l’évolution des pratiques en oncologie (CEPO). Gynecol Oncol. 2013;131:231–40.CrossRefPubMed
10.
Zurück zum Zitat Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi33–38.PubMed Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi33–38.PubMed
11.
Zurück zum Zitat Koh W-J, Greer BE, Abu-Rustum NR, et al. Uterine neoplasms, version 1. 2014. J Natl Compr Cancer Netw. 2014;12:248–80. Koh W-J, Greer BE, Abu-Rustum NR, et al. Uterine neoplasms, version 1. 2014. J Natl Compr Cancer Netw. 2014;12:248–80.
12.
Zurück zum Zitat Querleu D, Planchamp F, Narducci F, et al. Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut National du Cancer and the Société Française d’Oncologie Gynécologique. Int J Gynecol Cancer. 2011;21:945–50.CrossRefPubMed Querleu D, Planchamp F, Narducci F, et al. Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut National du Cancer and the Société Française d’Oncologie Gynécologique. Int J Gynecol Cancer. 2011;21:945–50.CrossRefPubMed
13.
Zurück zum Zitat Hogarth RM, Karelaia N. Heuristic and linear models of judgment: matching rules and environments. Psychol Rev. 2007;114:733–58.CrossRefPubMed Hogarth RM, Karelaia N. Heuristic and linear models of judgment: matching rules and environments. Psychol Rev. 2007;114:733–58.CrossRefPubMed
14.
Zurück zum Zitat Vlaev I, Chater N. Game relativity: how context influences strategic decision making. J Exp Psychol Learn Mem Cogn. 2006;32:131–49.CrossRefPubMed Vlaev I, Chater N. Game relativity: how context influences strategic decision making. J Exp Psychol Learn Mem Cogn. 2006;32:131–49.CrossRefPubMed
15.
Zurück zum Zitat Kattan MW, Scardino PT. Prediction of progression: nomograms of clinical utility. Clin Prostate Cancer 2002;1:90–6.CrossRefPubMed Kattan MW, Scardino PT. Prediction of progression: nomograms of clinical utility. Clin Prostate Cancer 2002;1:90–6.CrossRefPubMed
16.
Zurück zum Zitat Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol. 2011;8:261–71.CrossRefPubMed Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol. 2011;8:261–71.CrossRefPubMed
17.
Zurück zum Zitat Weigelt B, Banerjee S. Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol. 2012;24:554–63.CrossRefPubMed Weigelt B, Banerjee S. Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol. 2012;24:554–63.CrossRefPubMed
18.
Zurück zum Zitat Tian Q, Price ND, Hood L. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med. 2012;271:111–21.PubMedCentralCrossRefPubMed Tian Q, Price ND, Hood L. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med. 2012;271:111–21.PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Eastham JA, Kattan MW, Scardino PT. Nomograms as predictive models. Semin Urol Oncol. 2002;20:108–15.CrossRefPubMed Eastham JA, Kattan MW, Scardino PT. Nomograms as predictive models. Semin Urol Oncol. 2002;20:108–15.CrossRefPubMed
20.
Zurück zum Zitat Abu-Rustum NR, Zhou Q, Gomez JD, et al. A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. Gynecol Oncol. 2010;116:399–403.CrossRefPubMed Abu-Rustum NR, Zhou Q, Gomez JD, et al. A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. Gynecol Oncol. 2010;116:399–403.CrossRefPubMed
21.
Zurück zum Zitat AlHilli MM, Podratz KC, Dowdy SC, et al. Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer. Gynecol Oncol. 2013;131:103–08.CrossRefPubMed AlHilli MM, Podratz KC, Dowdy SC, et al. Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer. Gynecol Oncol. 2013;131:103–08.CrossRefPubMed
22.
Zurück zum Zitat AlHilli MM, Podratz KC, Dowdy SC, et al. Preoperative biopsy and intraoperative tumor diameter predict lymph node dissemination in endometrial cancer. Gynecol Oncol. 2013;128:294–9.CrossRefPubMed AlHilli MM, Podratz KC, Dowdy SC, et al. Preoperative biopsy and intraoperative tumor diameter predict lymph node dissemination in endometrial cancer. Gynecol Oncol. 2013;128:294–9.CrossRefPubMed
23.
Zurück zum Zitat Bendifallah S, Genin AS, Naoura I, et al. A nomogram for predicting lymph node metastasis of presumed stage I and II endometrial cancer. Am J Obstet Gynecol. 2012;207:197.e1–8.PubMed Bendifallah S, Genin AS, Naoura I, et al. A nomogram for predicting lymph node metastasis of presumed stage I and II endometrial cancer. Am J Obstet Gynecol. 2012;207:197.e1–8.PubMed
24.
Zurück zum Zitat Kamura T, Yahata H, Shigematsu T, et al. Predicting pelvic lymph node metastasis in endometrial carcinoma. Gynecol Oncol. 1999;72:387–91.CrossRefPubMed Kamura T, Yahata H, Shigematsu T, et al. Predicting pelvic lymph node metastasis in endometrial carcinoma. Gynecol Oncol. 1999;72:387–91.CrossRefPubMed
25.
Zurück zum Zitat Lee J-Y, Jung DC, Park SH, et al. Preoperative prediction model of lymph node metastasis in endometrial cancer. Int J Gynecol Cancer. 2010;20:1350–55.PubMed Lee J-Y, Jung DC, Park SH, et al. Preoperative prediction model of lymph node metastasis in endometrial cancer. Int J Gynecol Cancer. 2010;20:1350–55.PubMed
26.
Zurück zum Zitat Todo Y, Okamoto K, Hayashi M, et al. A validation study of a scoring system to estimate the risk of lymph node metastasis for patients with endometrial cancer for tailoring the indication of lymphadenectomy. Gynecol Oncol. 2007;104:623–28.CrossRefPubMed Todo Y, Okamoto K, Hayashi M, et al. A validation study of a scoring system to estimate the risk of lymph node metastasis for patients with endometrial cancer for tailoring the indication of lymphadenectomy. Gynecol Oncol. 2007;104:623–28.CrossRefPubMed
27.
Zurück zum Zitat Bendifallah S, Canlorbe G, Huguet F, et al. A risk scoring system to determine recurrence in early-stage type 1 endometrial cancer: a French Multicentre Study. Ann Surg Oncol. 2014; doi: 10.1245/s10434-014-3864-6 Bendifallah S, Canlorbe G, Huguet F, et al. A risk scoring system to determine recurrence in early-stage type 1 endometrial cancer: a French Multicentre Study. Ann Surg Oncol. 2014; doi: 10.​1245/​s10434-014-3864-6
28.
Zurück zum Zitat Bendifallah S, Canlorbe G, Arsène E, et al. French multicenter study evaluating the risk of lymph node metastases in early-stage endometrial cancer: contribution of a risk scoring system. Ann Surg Oncol. 2015; doi: 10.1245/s10434-014-4311-4 Bendifallah S, Canlorbe G, Arsène E, et al. French multicenter study evaluating the risk of lymph node metastases in early-stage endometrial cancer: contribution of a risk scoring system. Ann Surg Oncol. 2015; doi: 10.​1245/​s10434-014-4311-4
29.
Zurück zum Zitat Kondalsamy-Chennakesavan S, Yu C, Kattan MW, et al. Nomograms to predict isolated loco-regional or distant recurrence among women with uterine cancer. Gynecol Oncol. 2012;125:520–25.CrossRefPubMed Kondalsamy-Chennakesavan S, Yu C, Kattan MW, et al. Nomograms to predict isolated loco-regional or distant recurrence among women with uterine cancer. Gynecol Oncol. 2012;125:520–25.CrossRefPubMed
30.
Zurück zum Zitat Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol. 2003;13:111–16.CrossRefPubMed Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol. 2003;13:111–16.CrossRefPubMed
31.
Zurück zum Zitat Barlin JN, Soslow RA, Lutz M, et al. Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment. Int J Gynecol Cancer. 2013;23:1620–28.PubMedCentralCrossRefPubMed Barlin JN, Soslow RA, Lutz M, et al. Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment. Int J Gynecol Cancer. 2013;23:1620–28.PubMedCentralCrossRefPubMed
32.
Zurück zum Zitat Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol. 2014;15:e268–278.CrossRefPubMed Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol. 2014;15:e268–278.CrossRefPubMed
33.
Zurück zum Zitat Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:1404–11.CrossRefPubMed Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:1404–11.CrossRefPubMed
34.
Zurück zum Zitat Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–51.CrossRefPubMed Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–51.CrossRefPubMed
35.
Zurück zum Zitat Todo Y, Kato H, Kaneuchi M, et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010;375:1165–72.CrossRefPubMed Todo Y, Kato H, Kaneuchi M, et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010;375:1165–72.CrossRefPubMed
36.
Zurück zum Zitat Bendifallah S, Canlorbe G, Raimond E, et al. A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion. Br J Cancer. 2014; doi: 10.1038/bjc.2014.237 Bendifallah S, Canlorbe G, Raimond E, et al. A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion. Br J Cancer. 2014; doi: 10.​1038/​bjc.​2014.​237
37.
Zurück zum Zitat Bendifallah S, Canlorbe G, Collinet P, et al. Just how accurate are the major risk stratification systems for early-stage endometrial cancer? Br. J. Cancer (2015). doi:10.1038/bjc.2015.35 PubMed Bendifallah S, Canlorbe G, Collinet P, et al. Just how accurate are the major risk stratification systems for early-stage endometrial cancer? Br. J. Cancer (2015). doi:10.​1038/​bjc.​2015.​35 PubMed
38.
Zurück zum Zitat Silverman MB, Roche PC, Kho RM, et al. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma. Gynecol Oncol. 2000;77:1–7.CrossRefPubMed Silverman MB, Roche PC, Kho RM, et al. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma. Gynecol Oncol. 2000;77:1–7.CrossRefPubMed
39.
Zurück zum Zitat Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.CrossRef Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.CrossRef
40.
Zurück zum Zitat Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364–70.CrossRef Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364–70.CrossRef
41.
Zurück zum Zitat Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–87.CrossRefPubMed Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–87.CrossRefPubMed
42.
Zurück zum Zitat Abbott RD. Logistic regression in survival analysis. Am J Epidemiol. 1985;121:465–71.PubMed Abbott RD. Logistic regression in survival analysis. Am J Epidemiol. 1985;121:465–71.PubMed
43.
Zurück zum Zitat Hosmer DW, Hjort NL. Goodness-of-fit processes for logistic regression: simulation results. Stat Med. 2002;21:2723–38.CrossRefPubMed Hosmer DW, Hjort NL. Goodness-of-fit processes for logistic regression: simulation results. Stat Med. 2002;21:2723–38.CrossRefPubMed
44.
Zurück zum Zitat Steyerberg EW, Eijkemans MJ, Van Houwelingen JC, Lee KL, Habbema JD. Prognostic models based on literature and individual patient data in logistic regression analysis. Stat Med. 2000;19:141–60.CrossRefPubMed Steyerberg EW, Eijkemans MJ, Van Houwelingen JC, Lee KL, Habbema JD. Prognostic models based on literature and individual patient data in logistic regression analysis. Stat Med. 2000;19:141–60.CrossRefPubMed
45.
Zurück zum Zitat American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol. 2005;106:413–25.CrossRef American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol. 2005;106:413–25.CrossRef
46.
Zurück zum Zitat Ko EM, Funk MJ, Clark LH, Brewster WR. Did GOG99 and PORTEC1 change clinical practice in the United States? Gynecol Oncol. 2013;129:12–17.CrossRefPubMed Ko EM, Funk MJ, Clark LH, Brewster WR. Did GOG99 and PORTEC1 change clinical practice in the United States? Gynecol Oncol. 2013;129:12–17.CrossRefPubMed
47.
Zurück zum Zitat ASTEC study group, Kitchener H, Swart AM, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373:125–36.CrossRef ASTEC study group, Kitchener H, Swart AM, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373:125–36.CrossRef
48.
Zurück zum Zitat Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23.CrossRefPubMed Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23.CrossRefPubMed
49.
Zurück zum Zitat Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100:1707–16.CrossRefPubMed Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100:1707–16.CrossRefPubMed
50.
Zurück zum Zitat Nugent EK, Bishop EA, Mathews CA, et al. Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma? Gynecol Oncol. 2012;125:94–98.CrossRefPubMed Nugent EK, Bishop EA, Mathews CA, et al. Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma? Gynecol Oncol. 2012;125:94–98.CrossRefPubMed
51.
Zurück zum Zitat Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987;60:2035–41.PubMed Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987;60:2035–41.PubMed
52.
Zurück zum Zitat Podratz KC, Mariani A, Webb MJ. Staging and therapeutic value of lymphadenectomy in endometrial cancer. Gynecol Oncol. 1998;70:163–64.CrossRefPubMed Podratz KC, Mariani A, Webb MJ. Staging and therapeutic value of lymphadenectomy in endometrial cancer. Gynecol Oncol. 1998;70:163–64.CrossRefPubMed
53.
Zurück zum Zitat Mariani A, Webb MJ, Keeney GL, Lesnick TG, Podratz KC. Surgical stage I endometrial cancer: predictors of distant failure and death. Gynecol Oncol. 2002;87:274–80.CrossRefPubMed Mariani A, Webb MJ, Keeney GL, Lesnick TG, Podratz KC. Surgical stage I endometrial cancer: predictors of distant failure and death. Gynecol Oncol. 2002;87:274–80.CrossRefPubMed
54.
Zurück zum Zitat Lurain JR, Rice BL, Rademaker AW, et al. Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol. 1991;78:63–69.PubMed Lurain JR, Rice BL, Rademaker AW, et al. Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol. 1991;78:63–69.PubMed
55.
Zurück zum Zitat Kim HS, Suh DH, Kim MK, et al. Systematic lymphadenectomy for survival in patients with endometrial cancer: a meta-analysis. Jpn J Clin Oncol. 2012;42:405–12.CrossRefPubMed Kim HS, Suh DH, Kim MK, et al. Systematic lymphadenectomy for survival in patients with endometrial cancer: a meta-analysis. Jpn J Clin Oncol. 2012;42:405–12.CrossRefPubMed
56.
Zurück zum Zitat Luomaranta, A., Leminen, A. & Loukovaara, M. Prediction of lymph node and distant metastasis in patients with endometrial carcinoma: a new model based on demographics, biochemical factors, and tumor histology. Gynecol Oncol. 2013;129:28–32.CrossRefPubMed Luomaranta, A., Leminen, A. & Loukovaara, M. Prediction of lymph node and distant metastasis in patients with endometrial carcinoma: a new model based on demographics, biochemical factors, and tumor histology. Gynecol Oncol. 2013;129:28–32.CrossRefPubMed
57.
Zurück zum Zitat Koskas M, Genin AS, Graesslin O, et al. Evaluation of a method of predicting lymph node metastasis in endometrial cancer based on five pre-operative characteristics. Eur J Obstet Gynecol Reprod Biol. 2014;172:115–19.CrossRefPubMed Koskas M, Genin AS, Graesslin O, et al. Evaluation of a method of predicting lymph node metastasis in endometrial cancer based on five pre-operative characteristics. Eur J Obstet Gynecol Reprod Biol. 2014;172:115–19.CrossRefPubMed
58.
Zurück zum Zitat Bendifallah S, Canlorbe G, Raimond E, et al. An external validation study of nomograms designed to predict isolated loco-regional and distant endometrial cancer recurrences: how applicable are they? Br J Cancer. 2013; doi: 10.1038/bjc.2013.500 Bendifallah S, Canlorbe G, Raimond E, et al. An external validation study of nomograms designed to predict isolated loco-regional and distant endometrial cancer recurrences: how applicable are they? Br J Cancer. 2013; doi: 10.​1038/​bjc.​2013.​500
59.
Zurück zum Zitat Kang S, Lee JM, Lee JK, et al. A Web-based nomogram predicting para-aortic nodal metastasis in incompletely staged patients with endometrial cancer: a Korean Multicenter Study. Int J Gynecol Cancer. 2014;24:513–19.CrossRefPubMed Kang S, Lee JM, Lee JK, et al. A Web-based nomogram predicting para-aortic nodal metastasis in incompletely staged patients with endometrial cancer: a Korean Multicenter Study. Int J Gynecol Cancer. 2014;24:513–19.CrossRefPubMed
60.
Zurück zum Zitat Brinton LA, Felix AS, McMeekin DS, et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013;129:277–84.PubMedCentralCrossRefPubMed Brinton LA, Felix AS, McMeekin DS, et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013;129:277–84.PubMedCentralCrossRefPubMed
61.
Zurück zum Zitat Polterauer S, Zhou Q, Grimm C, et al. External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer. Gynecol Oncol. 2012;125:526–30.CrossRefPubMed Polterauer S, Zhou Q, Grimm C, et al. External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer. Gynecol Oncol. 2012;125:526–30.CrossRefPubMed
62.
Zurück zum Zitat Koskas M, Bendifallah S, Luton D, Darai E, Rouzier R. Independent external validation of radiotherapy and its impact on the accuracy of a nomogram for predicting survival of women with endometrial cancer. Gynecol Oncol. 2011;123:214–20.CrossRefPubMed Koskas M, Bendifallah S, Luton D, Darai E, Rouzier R. Independent external validation of radiotherapy and its impact on the accuracy of a nomogram for predicting survival of women with endometrial cancer. Gynecol Oncol. 2011;123:214–20.CrossRefPubMed
63.
Zurück zum Zitat AlHilli MM, Mariani A, Bakkum-Gamez JN, et al. Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer. Gynecol Oncol. 2014;133:485–93.PubMedCentralCrossRefPubMed AlHilli MM, Mariani A, Bakkum-Gamez JN, et al. Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer. Gynecol Oncol. 2014;133:485–93.PubMedCentralCrossRefPubMed
64.
Zurück zum Zitat Creutzberg CL, van Stiphout RG, Nout RA, et al. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 Trials. Int J Radiat Oncol Biol Phys. 2015;91:530–39.CrossRefPubMed Creutzberg CL, van Stiphout RG, Nout RA, et al. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 Trials. Int J Radiat Oncol Biol Phys. 2015;91:530–39.CrossRefPubMed
65.
Zurück zum Zitat Lakhman Y, Yakar D, Goldman DA, et al. Preoperative CT-based nomogram for predicting overall survival in women with non-endometrioid carcinomas of the uterine corpus. Abdom Imaging 2014; doi: 10.1007/s00261-014-0337-0 Lakhman Y, Yakar D, Goldman DA, et al. Preoperative CT-based nomogram for predicting overall survival in women with non-endometrioid carcinomas of the uterine corpus. Abdom Imaging 2014; doi: 10.​1007/​s00261-014-0337-0
66.
Zurück zum Zitat Bendifallah S, Canlorbe G, Raimond E, et al. External validation of nomograms designed to predict lymphatic dissemination in patients with early-stage endometrioid endometrial cancer: a multicenter study. Am J Obstet Gynecol. 2014; doi: 10.1016/j.ajog.2014.06.058 Bendifallah S, Canlorbe G, Raimond E, et al. External validation of nomograms designed to predict lymphatic dissemination in patients with early-stage endometrioid endometrial cancer: a multicenter study. Am J Obstet Gynecol. 2014; doi: 10.​1016/​j.​ajog.​2014.​06.​058
67.
68.
Zurück zum Zitat Kattan MW. Nomograms. Introduction. Semin Urol Oncol. 2002;20:79–81.PubMed Kattan MW. Nomograms. Introduction. Semin Urol Oncol. 2002;20:79–81.PubMed
Metadaten
Titel
Predictive Modeling: A New Paradigm for Managing Endometrial Cancer
verfasst von
Sofiane Bendifallah, MD
Emile Daraï, MD, PhD
Marcos Ballester, MD, PhD
Publikationsdatum
01.03.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 3/2016
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4924-2

Weitere Artikel der Ausgabe 3/2016

Annals of Surgical Oncology 3/2016 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.